NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 YTD Q2 P&L / Income Statement

NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

1,773,500,000 US dollars

Cost of revenue (calculated)

36,900,000 US dollars

Gross profit (calculated)

1,736,600,000 US dollars

Operating expenses (calculated)

1,391,700,000 US dollars

Operating income

344,900,000 US dollars

Total other income, net

64,100,000 US dollars

Income before provision for income taxes

409,000,000 US dollars

Provision for income taxes

66,700,000 US dollars

Net income

342,300,000 US dollars

Net product sales

1,765,300,000 US dollars

Collaboration revenues

8,200,000 US dollars

Cost of revenues, excluding amortization of acquired intangible assets

36,900,000 US dollars

Research and development

622,900,000 US dollars

Acquired in-process research and development

22,700,000 US dollars

Selling, general, and administrative

758,200,000 US dollars

Amortization of acquired intangible assets

16,500,000 US dollars

Gain on sale of business, net of transaction costs

negative 28,600,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.